Join
Live feed
·
INSIDERFilingvia Quantisnow
Recursion Pharmaceuticals Inc. logo

Chief R&D Commercial Officer Khan Najat was granted 84,925 shares, increasing direct ownership by 13% to 753,122 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
RXRX· Recursion Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RXRX (Recursion Pharmaceuticals Inc.) and more on Quantisnow.